ISM001-055 was shown to have attenuated cellular senescence through the suppression of various aging processes, thus showing potential as a senomorphic drug.

As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $39 price ...

A multi-omics study reveals that impaired branched-chain amino acid (BCAA) catabolism is a key driver of sarcopenia, suggesting it as a potential therapeutic target.

Today’s burning question from Cochlear's (ASX:COH) poorly received interim results is whether users are on a buyer’s strike ahead of upgraded implants and processors – or whether the problems are more ...

Aubrey de Grey had a large mouse study of combinations of antiaging treatments. They did show that combination treatments did ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

The FDA has granted Fast Track designation to eRapa, an encapsulated form of rapamycin, for the treatment of familial adenomatous polyposis.

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of ...